Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies.
The data support the development of the MYC/GSPT1 degrader GT19630 as a therapeutic strategy of MYC-driven hematologic malignancies as a therapeutic strategy of therapy-resistant hematologic malignancies.